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E M B O L I Z AT I O N

Yttrium-90
Radioembolization
Mapping and Therapy
What to do and what to avoid.
BY PAVAN K. KAVALI, MD; RIPAL T. GANDHI, MD; AND SUVRANU GANGULI, MD

T

he use of minimally invasive procedures to
manage primary and metastatic liver cancer has become increasingly common with
the rising incidence of hepatic malignancies.
Radioembolization, also known as selective internal
radiation therapy or radiation microsphere therapy, is a
complex yet minimally invasive procedure that aims
to selectively deliver high doses of internal radiation
using an intra-arterial infusion of microspheres loaded
with the radionuclide yttrium-90 (Y-90).1,2 Indications
for Y-90 radioembolization include managing primary
liver malignancies and metastatic disease of the hepatic
parenchyma.3 Patient selection criteria is covered in
the literature, and some radioembolic agents of choice
currently include SIR-Spheres Y-90 resin microspheres
(Sirtex Medical Inc.) and glass TheraSpheres (BTG
International Ltd.).4,5
OVERVIEW
Radioembolization treatment is a two-stage outpatient process: the preparation/mapping stage and the
treatment stage. In our institutions, patients are carefully
evaluated, often incorporating multidisciplinary evaluation from medical oncology, surgical oncology, radiation
oncology, transplant surgery, hepatology, and interventional radiology. After clinical evaluation by interventional radiology, appropriate patients are scheduled for an
angiographic preradioembolization mapping procedure,
with a treatment date preselected 7 to 10 days after the
mapping procedure.
The mapping procedure serves two distinct purposes. First, delineation of the hepatic arterial anatomy
is important for eventual dose delivery and to avoid
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nontarget delivery. Variant hepatic arterial anatomy
is common and occurs in up to 45% of patients (see
Case Report 1).6 Determining and isolating the hepatic
arterial branches perfusing the tumor(s) can help avoid
possible complications. In addition, this procedure may
be used to exclude, by means of embolization, hepaticomesenteric collaterals.
Second, assessment of hepatopulmonary shunting is vital to determine the eventual radiation dose
given to the patient.7 The degree of shunting is estimated through intra-arterial infusion of technetium-99
m-labeled macroaggregated albumin (Tc-99m MAA)
(4–5 mCi) and subsequent measurement of the lung and
liver activity.5 Although presence of a hepatopulmonary
shunt is not an absolute contraindication, the radiation
dose to the lungs should not exceed 30 Gy in a single
setting, and the cumulative dose to the lungs should
not exceed 50 Gy. The MAA scan also helps identify
potential extrahepatic uptake of Tc-99m MAA, and we
routinely perform single photon emission computed
tomography (SPECT)/CT rather than planar imaging
because we prefer the extra anatomic detail it provides
(as seen in Case Report 1).
We prefer to position the microcatheter in the same
location between the mapping procedure and the treatment, as we believe the information provided by the
MAA scan is the most accurate depiction of the subsequent treatment. After the treatment, it is standard practice to obtain a bremsstrahlung SPECT scan. We often do
not obtain bremsstrahlung SPECT scan because it typically does not change the treatment and can extend the
patient’s time in the department. We routinely prescribe
methylprednisolone and recommend continuation of a
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A: A 55-year-old man with bilobar metastatic colorectal cancer. A digital subtraction angiogram of the celiac artery from a
transradial approach using a 110-cm, 5-F Sarah catheter shows splenic and common hepatic arteries. The common hepatic artery divides into the gastroduodenal and proper hepatic arteries.
B: A selective microcatheter angiogram of the proper hepatic artery shows normal opacification of the right hepatic
artery status after coil embolization of the GDA (straight arrow). The right gastric artery is not visualized; however, there
is lack of opacification of the lateral segment of the left hepatic lobe (block arrow) raising suspicion of the presence of a
replaced left hepatic artery from the left gastric artery (also known as a gastrohepatic trunk).
C: A superselective angiogram of the left gastric artery shows replaced left hepatic artery arising (straight arrow) with
hepatic parenchymal opacification.
D: The decision was made to redistribute the flow of the left hepatic lobe to the proper hepatic artery. The replaced left hepatic
artery origin was embolized (straight arrow), and selective left gastric arteriography shows opacification of gastric branches.
E: Subsequent superselective angiography from the proper hepatic artery shows coils in the replaced left hepatic artery
with immediate redistribution of the left hepatic lobe arterial supply (straight arrow) from the proper hepatic artery.
Tc-99m MAA was infused from this position to cover the whole liver.
F: Unexpectedly, although the subsequent SPECT/CT scan coronal reformat after Tc-99m MAA instillation shows coverage
of the entire liver, there is significant deposition in the duodenum (white arrow). It was surmised that a supraduodenal
artery branch was present, and it was not well visualized on the angiogram.
G: In order to avoid duodenal deposition, the decision was made to split the Y-90 treatment dose for administration. Nonsubtracted angiography performed during treatment shows a 6-F Ansel sheath (block arrow) from a femoral
approach positioned in the common hepatic artery with two microcatheters positioned in the right and middle hepatic
arteries (straight arrows). The lobar doses were administered in sequential fashion.

proton pump inhibitor for at least 1 month after the procedure. We do not routinely prescribe antibiotic prophylaxis for patients after the procedure. Patients are scheduled for a clinic visit and a 1- to 3-month follow-up MRI or
CT angiogram (CTA) of the abdomen for primary hepatic
malignancies versus a positron emission tomography/CT
for metastatic tumors to assess response to therapy.

MAPPING STUDY AND EMBOLIZATION
In our practice, we have predominantly shifted toward a
transradial approach (TRA) to gain access to the abdominal aorta, although we still utilize a transfemoral approach
as needed, and choice of access site tends to be operator
dependent. We use a 5-F Glidesheath Slender (Terumo
Interventional Systems) via the left radial artery. The
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A: A 62-year-old woman with bilobar metastatic ocular melanoma. Digital subtraction angiography of the common
hepatic artery shows conventional hepatic arterial anatomy with the presence of a right gastric artery arising from the left
hepatic artery (arrow).
B: The GDA was subsequently embolized with a plug (straight arrow), and attempts to catheterize the right gastric artery
were unsuccessful. Selective angiography of the left gastric artery (curved arrow) opacifies the right gastric artery origin
through its collateralization and subsequently the right and left hepatic arteries.
C: The microcatheter tip was subsequently advanced to the right gastric artery via the left gastric artery connection, and
angiography opacifies the right and left hepatic arteries from this position.
D: Coil embolization was then performed on the right gastric artery origin through the microcatheter placed from the left
gastric artery.
E: Subsequent superselective microcatheter angiography from the proper hepatic artery shows no further filling of the
right gastric artery or the GDA. Tc-99m MAA was infused from this position to cover the whole liver.

technical details of transradial access are discussed in the
literature.8 In most cases, a 110-cm Sarah, Jacky, or tiger
Optitorque catheter (Terumo Interventional Systems) and
a 1.5-mm J-Tip Glidewire (Terumo Interventional Systems)
or Bentson guidewire (Cook Medical) are used to traverse
the subclavian artery and advance into the abdominal
aorta to select the mesenteric vessels. If difficulty accessing
the descending aorta is encountered due to a tortuous
68 ENDOVASCULAR TODAY APRIL 2016 VOL. 15, NO. 4

aortic arch, a 110-cm pigtail catheter and an exchangelength, angled, stiff Glidewire can almost always navigate
the tortuosity, which is then exchanged for the mesenteric
selective catheter. There is some hindrance to cone beam
CT use with TRA, which may require a learning curve for
the physicians and technologists, but complex embolization can routinely be done from this approach with the
appropriate equipment.
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Thorough angiography is necessary; however, we do
not perform an aortography, because it is an unnecessary
contrast dye load. All patients undergo cross-sectional
imaging including a CTA or MRI of the abdomen, which
should be studied carefully in advance. We always start
with a superior mesenteric artery (SMA) arteriogram to
assess for the presence of replaced or accessory hepatic
arteries; however, a thin-cut CTA can delineate these
vessels as well and can sometimes obviate the need for
an SMA angiogram. The arteriogram is obtained at a
rate of 4 to 6 mL/sec for 24 to 30 mL. This is allowed
to extend into the venous phase to assess for patency
of the portal vein. The celiac artery is then selectively
catheterized to evaluate the hepatic arterial anatomy.
A celiac arteriogram is obtained at rates of 4 to 5 mL/sec
for 16 to 25 mL. If an SMA angiogram is not obtained,
celiac angiography is performed in the venous phase
to evaluate the portal vein. Subsequently, a 3-F microcatheter of choice (eg, Renegade Hi-Flo, Direxion [both
Boston Scientific Corporation], or Progreat [Terumo
Interventional Systems]) is used to perform superselective angiography of the common, right, and left hepatic
arteries. Angiography of the common hepatic artery is
performed at a rate of 3 to 4 mL/sec for 12 to 16 mL,
and angiography of the right and left hepatic arteries is
performed at a rate of 2 to 3 mL/sec for up to 12 mL.
A selective left gastric arteriogram may be considered
to evaluate for replaced or accessory left hepatic arteries. Cone beam CT is used extensively in our practice to
delineate the anatomy, including the arterial feeders for the
tumor(s), and to assess treatment coverage of the liver.
Depending on the lesion location and the arteries
identified via angiography, prophylactic embolization
of the supraduodenal, gastroduodenal (GDA), right
gastric, accessory gastric, falciform, or inferior phrenic
arteries may be performed. We prefer not to embolize
the cystic artery, even when identified in the treatment
zone, as the incidence of radiation-induced cholecystitis
is low. Embolization of the right gastric artery may be
performed by entering via the left gastric artery when it
cannot be catheterized from its hepatic origin (see Case
Report 2). Embolization is accomplished with either
detachable or nondetachable coils and plugs. We typically use a combination of these embolic agents. Use of
high-flow microcatheters has been associated with difficulty deploying some detachable coils, and familiarity
with which kinds of coils can and cannot easily deploy
through a given microcatheter is extremely beneficial.
We believe the benefits of a high-flow microcatheter,
which provides better diagnostic angiograms with higher
flow rates and better opacification, outweigh the drawbacks with coils.
70 ENDOVASCULAR TODAY APRIL 2016 VOL. 15, NO. 4

Being mindful of which vessels the microspheres
could reflux into often guides us to which vessel may
require embolization. If the right hepatic artery is the
target vessel and the first vessel the microspheres
would reflux into is the left hepatic artery, embolization is typically not performed. Careful evaluation for
the presence of the right gastric artery should be performed when infusing Y-90 in the left hepatic artery.
If therapy is being infused from the proper hepatic
artery, the GDA and right gastric artery likely need
to be embolized. When embolizing the GDA, the key
aspect is to ensure embolization over a long length and
back up to the origin of the vessel to minimize chances
of recanalization. We have also had instances of collateral formation from the distal hepatic arteries to
the distal GDA when only the proximal portion of the
GDA has been occluded. For this reason, we also do not
embolize the GDA when we believe it is unnecessary,
such as in a lobar treatment when the microcatheter
can be placed distally, away from the GDA origin.9 We
often prefer starting with soft detachable coils distally,
such as Concerto coils (Medtronic), to understand the
optimal coil sizes and ensure more precise placement.
This step may be followed by detachable Interlock
(Boston Scientific Corporation) coils or pushable coils
such as Tornado or Nester coils (both Cook Medical),
which have more body and thrombogenicity. We then
often use detachable coils again when approaching
the origin of the vessel to prevent extension into the
hepatic artery. Microvascular plugs, such as the MVP
microvascular plug (Medtronic) and the Amplatzer
Vascular Plug 4 (St. Jude Medical, Inc.), can also be
used to embolize the GDA. The right gastric artery
can be embolized with coils or a microvascular plug.
Completion angiography performed after embolization
should not show any further flow.
Small accessory left hepatic or right hepatic arteries may be embolized to redistribute perfusion to the
native left or right hepatic artery for a single microcatheter administration. However, one should be wary of
attempting intrahepatic redistribution of perfusion with
segment IV or other intrahepatic lobar segments, as predicting whether the left or right hepatic artery will take
over the perfusion in these situations can be difficult.
LOBAR VERSUS WHOLE LIVER TREATMENT
In cases of primary hepatic malignancy, including
hepatocellular carcinoma, we prefer segmental or lobar
treatments, even with bilobar disease. As a result, the
infusion microcatheter can be placed distally into either
the right or left hepatic arteries. Lobar therapy often
obviates the need for embolization of branch vessels
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off the common hepatic artery. In cases of metastatic
disease, particularly colorectal cancer, data from the
SIRFLOX trial are based on whole liver Y-90 therapy.10
Therefore, in metastatic disease with bilobar tumors, we
perform both staged treatments (but mostly whole liver
treatments), and this is dependent on operator preference. For metastatic neuroendocrine disease, given the
side effects we have seen from tumor cell death and
secretion of peptides and hormones, we still opt for
lobar treatments in bilobar disease.
If there is challenging hepatic anatomy where an
infusion cannot be performed from the proper hepatic
artery safely, the Y-90 dose can be split between two
separate microcatheters, which are placed distally into
the hepatic lobes. This may be done with sequential
treatments in the same setting using a 5-F catheter and
microcatheter that are deposed in between treatments.
Or, we often use a 6-F Flexor Check-Flo Introducer
Ansel 2 guiding sheath (Cook Medical) into the ostium
of the celiac artery from a transfemoral approach, followed by placement of two separate microcatheters
deep into the right and left hepatic arteries so that each
microcatheter can be infused temporally and then disposed of at once.
OUTCOMES
Several studies have demonstrated radioembolization
therapy to be safe and effective in the treatment of primary and metastatic hepatic malignancies.11 Early analysis of a prospective cohort of 20 patients treated with
Y-90 therapy reported significant outcomes with respect
to both survival and quality of life.12 Radioembolization
has also been shown to be safe and effective in unresectable hepatocellular carcinoma, with 79% showing tumor
response when percent reduction and/or tumor necrosis
were used as a composite measure of tumor response.13
With respect to metastatic disease from colorectal cancer, recent data from the landmark SIRFLOX trial demonstrated statistically significant median liver progressionfree survival when Y-90 was used in conjunction with
standard chemotherapy.14 However, no improvement
in overall progression-free survival was identified when
compared to chemotherapy alone. Combination of
data from the SIRFLOX trial and two other trials is being
awaited to evaluate overall survival in a large cohort of
patients. In metastatic neuroendocrine tumors, a review
of available literature demonstrates safe and effective use
of radioembolization in liver-dominant disease.15
CONCLUSION
Selective internal radiation therapy has been shown
to be an effective outpatient therapy for patients with

either primary hepatic malignancies or metastatic liver
disease.11-15 A thorough angiographic mapping study
with embolization of some of the major branches of
the common hepatic and proper hepatic arteries is a
major component of the two-stage process for Y-90
therapy. Lobar or segmental therapy sometimes obviates the need for embolization in our recent experience; however, new users should be cautious, as the
repercussions of nontarget delivery of Y-90 microspheres can be significant. n
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